Scale Up Sample Clauses

Scale Up i. End User may request to scale up the Performance Level or add new environments during the Subscription Term by contacting the Bizagi Authorized Reseller. Such Bizagi Authorized Reseller will coordinate with Bizagi to comply with such request. End User will be required to pay any fees to the Bizagi Authorized Reseller resulting from such scale up in Performance Level in accordance with the payment terms of its agreement with the Bizagi Authorized Reseller.

Scale Up lf Forty Seven is able to secure a minimum of [*] scale manufacturing cGMP Batch with Lonza (subject to availability) through contractually binding commitment then Lonza will release Forty Seven for [*] and the [*]; provided that a notice for such change must be given by Forty Seven at least [*].

Scale Up. CLU up and running, pressure testing of “killer issues” completed.

Scale Up i. End User may request to scale up the Performance Level for any of its Environments during the Subscription Term by contacting the Bizagi Authorized Reseller. Such Bizagi Authorized Reseller will coordinate with Xxxxxx to comply with such request. End User will be required to pay any fees to the Bizagi Authorized Reseller resulting from such scale up in Performance Level in accordance with the payment terms of its agreement with the Bizagi Authorized Reseller. ii. Automatic Scale Up / BPU Report. Bizagi will generate a BPU usage report on a monthly basis which shows End User’s BPU consumption during the previous month (“BPU Report”). If the BPU Report shows that End User has exceeded the maximum number of BPU’s included in the contracted Performance Level as permitted in its subscription for two consecutive months and End User fails to upgrade to the appropriate Performance Level during such two (2) month period, then Bizagi will notify the Bizagi Authorized Reseller and automatically scale up End User to the appropriate Performance Level. The appropriate Performance Level will be determined based on the average BPU usage during the previous two (2) month period. End User will be required to pay any fees to the Bizagi Authorized Reseller resulting from such scale up.

Scale Up. Following the successful technology transfer, upon request by Bioamber and subject to [***]. Cargill shall invoice Bioamber [***] U.S. Dollars (US$[***]) per man-day provided, not inclusive of taxes or other governmental fees, and further adjusted for inflation at the time it goes into effect. Cargill shall [***].

Scale Up. Following the successful technology transfer, upon request by Bioamber and subject to Cargill’s availability of appropriate resources, Cargill will enter at its sole discretion into a services agreement with Bioamber to assist in the fermentation scale-up of using Modified CB1 obtained under Milestones 2 and 3 for producing succinic acid and salts thereof at a single Bioamber facility or a facility designated by Bioamber. Cargill shall invoice Bioamber [***] U.S. Dollars (US$[***]) per man-day provided, not inclusive of taxes or other governmental fees, and further adjusted for inflation at the time it goes into effect. Cargill shall have no obligation to perform scale-up work at Cargill facilities.

Scale Up. In the event that Phytera engages in scale up manufacturing of VHEs or OVLSs pursuant to Section 3.5, Chiron shall reimburse Phytera for its fairly allocated costs associated with such scale up manufacturing.

Scale Up. Upon receipt of notice of ACS's acceptance of the initial lot which yields those vials of Product produced in accordance with Paragraph 3.1.3, Prima Pharm shall promptly begin scale-up of the Process to demonstrate that commercially practicable yields of Product can be achieved with the Process so as to meet ACS's Product requirements. On or before July 1, 1997, Prima Pharm shall provide to ACS (i) a written report confirming the use of the Process to successfully make at least three (3) consecutive lots of seven thousand (7,000) vials of Product containing eleven thousand (11,000) Units of Hyaluronidase for corneaplasty and seven thousand (7,000) vials of Product containing eight thousand (8,000) Units of Hyaluronidase for use in the vitreous humor, in each case meeting all U.S.P. requirements, (ii) a full chemical analysis of each such lot of Product, (iii) a one hundred (100) vial sample from each such lot of Product, and (iv) such other information as ACS may reasonably request. Within sixty (60) days following receipt of such report, analysis, and information, ACS shall notify Prima Pharm whether the development of the Process is complete. In the event that ACS notifies Prima Pharm that further development of the Process is required, the parties shall confer to determine what further development activities are necessary, and the compensation, if any, that Prima Pharm shall receive for such development.

Scale Up. In order to facilitate the Manufacture of Marketed Product, SURMODICS agrees to accomplish, at its expense and with MERCK’s input and to MERCK’s reasonable satisfaction, the Manufacturing activities set forth in Schedule 2.6, within the time frames specified therein.[*]

Scale Up. The CMs shall initially scale-up the Facilities (as defined in Section 6.2) and equipment based on an initial scale-up level determined by the Steering Committee. Unless delayed as a result of an action (or inaction) by INHALE, [**]; provided any changes to the DMR or Manufacturing Requirements made after the Effective Date may affect the scale-up date, and the Parties agree to monitor such potential delays through the change control procedure set forth in Section 3.9. [**] Thereafter, the CMs shall scale-up additional capacity to meet the Agreed Capacity Levels.